BIOS:EURONEXT BRUSSELSBioSenic Analysis
Data as of 2026-05-26 - not real-time
$25.89
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Pulse Biosciences (BIOS) is trading well above its short‑ and long‑term moving averages, with the price comfortably above the 20‑day SMA (≈22.5) and the 200‑day SMA (≈17.8). Technical momentum indicators are bullish – RSI sits around 60, MACD is in a bullish crossover, and volume is increasing – suggesting short‑term price strength.
However, the fundamentals tell a starkly different story: the company reports negligible revenue (≈$0.75 M) with negative gross and operating margins, a trailing EPS loss of $1.10, and a massive cash burn reflected in negative operating and free cash flow. Valuation multiples are extreme (price‑to‑sales > 2,300 and price‑to‑book > 21), and the forward PE is deeply negative. Recent earnings showed a modest EPS beat but the stock fell sharply, underscoring market skepticism. The combination of high volatility (≈99% 30‑day) and a beta above 2 amplifies risk, while regulatory approval hurdles in the medical‑device space add further uncertainty.
However, the fundamentals tell a starkly different story: the company reports negligible revenue (≈$0.75 M) with negative gross and operating margins, a trailing EPS loss of $1.10, and a massive cash burn reflected in negative operating and free cash flow. Valuation multiples are extreme (price‑to‑sales > 2,300 and price‑to‑book > 21), and the forward PE is deeply negative. Recent earnings showed a modest EPS beat but the stock fell sharply, underscoring market skepticism. The combination of high volatility (≈99% 30‑day) and a beta above 2 amplifies risk, while regulatory approval hurdles in the medical‑device space add further uncertainty.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical setup (price above SMA20/50/200, MACD bullish)
- Recent earnings beat but post‑earnings sell‑off
- High short‑term volatility and beta
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Continued cash burn and negative margins
- Uncertainty around product commercialization and regulatory approvals
- Valuation remains far above fundamentals
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Lack of revenue growth and persistent losses
- Extreme valuation multiples with no clear path to profitability
- Elevated sector and regulatory risks in medical‑device market
Key Metrics & Analysis
Financial Health
P/E Ratio-29.4
ROE-80.72%
ROA-45.03%
Debt/Equity10.79
P/B Ratio21.8
Op. Cash Flow$-55196000
Free Cash Flow$-29080124
Industry P/E27.6
Technical Analysis
TrendBullish
RSI60.7
Support$18.36
Resistance$27.98
MA 20$22.47
MA 50$21.95
MA 200$17.77
MACDBullish
VolumeIncreasing
Fear & Greed Index91.8
Valuation
Target Price$30.00
Upside/Downside15.87%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.28
Volatility99.04%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.